Aethlon Medical, Inc. (AEMD)
NASDAQ: AEMD · IEX Real-Time Price · USD
2.19
+0.01 (0.46%)
Dec 29, 2023, 4:00 PM EST - Market closed
Company Description
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States.
It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.
The company was founded in 1999 and is based in San Diego, California.
Aethlon Medical, Inc.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 15 |
| CEO | James B. Frakes M.B.A. |
Contact Details
Address: 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 United States | |
| Phone | 858-459-7800 |
| Website | aethlonmedical.com |
Stock Details
| Ticker Symbol | AEMD |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0000882291 |
| CUSIP Number | 00808Y307 |
| ISIN Number | US00808Y4061 |
| Employer ID | 13-3632859 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Charles J. Fisher Jr., M.D. | Chief Executive Officer, Director and Member of Extracorporeal Therapy Advisory Board |
| Steven P. Larosa M.D. | Chief Medical Officer and Acting Chief Scientific Officer |
| Guy F. Cipriani BS (Eng.), MBA | Senior Vice President, Chief Business Officer and Director |
| James B. Frakes M.B.A. | Chief Financial Officer, Senior Vice President of Finance and Secretary |
| Sunil Sawhney | Head of Clinical Studies |
| Dr. Richard H. Tullis Ph.D. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 22, 2023 | 8-K/A | [Amend] Current report |
| Nov 27, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |
| Nov 14, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 8-K | Current Report |
| Oct 4, 2023 | 8-K | Current Report |
| Sep 18, 2023 | 8-K | Current Report |
| Aug 10, 2023 | 10-Q | Quarterly Report |
| Aug 10, 2023 | 8-K | Current Report |
| Jul 27, 2023 | ARS | Filing |